Janus Henderson Group PLC Ventyx Biosciences, Inc. Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.08 - $31.18 $3.51 Million - $52.7 Million	-1,688,710 Reduced 98.94%	18,074 $44,000
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $1.77 Million - $2.4 Million	-59,523 Reduced 3.37%	1,706,784 $59.3 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $4.79 Million - $6.64 Million	167,891 Added 10.5%	1,766,307 $57.9 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $3.97 Million - $6.28 Million	134,644 Added 9.2%	1,598,416 $53.5 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $3.61 Million - $5.43 Million	149,233 Added 11.35%	1,463,772 $48 Million
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $7.47 Million - $22.9 Million	-590,708 Reduced 31.0%	1,314,539 $45.9 Million
Q2 2022 Aug 15, 2022	SELL	$11.95 - $18.75 $2.73 Million - $4.29 Million	-228,607 Reduced 10.71%	1,905,247 $23.3 Million
Q1 2022 May 16, 2022	SELL	$10.0 - $19.98 $326,780 - $652,906	-32,678 Reduced 1.51%	2,133,854 $28.2 Million
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $30.8 Million - $50 Million	2,166,532 New	2,166,532 $40.8 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.